Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRUK
Biotech
Merck KGaA spinout iOnctura raises cash for cancer trials
Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.
Nick Paul Taylor
Jan 23, 2020 7:40am
Phastar nabs AZ, CRUK veteran as data science lead
Sep 12, 2019 7:40am
Ono pumps cash into U.K. immuno-oncology R&D effort
Mar 27, 2019 9:00am
Stemline licenses RET inhibitor from U.K. cancer group
Mar 11, 2019 9:53am
U.K. commits to EU Clinical Trial Regulation after Brexit
Apr 24, 2018 7:40am
CRUK to use AZ’s DNA med in head and neck cancer test
Nov 23, 2017 7:00pm
